Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Rose who wrote (119391)	3/5/2001 6:15:51 PM
From: H James Morris	Read Replies (1) \| Respond to of 164684

>OT: so what do you attribute it to here? America's constitutional right to bear arms. That means any idiot can buy a gun! Then, that means everyone needs to run out, and buy a gun to protect themselves from the idiots.

To: Robert Rose who wrote (119391)	3/7/2001 12:26:51 PM
From: H James Morris	Respond to of 164684

Rob, bought SGEN today at 7.75. The reason behind my thinking is if they ever need anymore money there's a place they can go. Also, investing in cancer research makes me feel good. I assume you know BG's mother died of breast cancer. >BOTHELL, Wash., March 7 (Reuters) - Seattle Genetics Inc. (NASDAQ:SGEN), a cancer drug firm whose major backers include Microsoft Corp. (NASDAQ:MSFT) co-founders Bill Gates and Paul Allen, on Wednesday said it priced seven million shares of common stock at $7.00 per share in an initial public offering. The price is below the already-lowered $8 to $10 a share price range Seattle Genetics announced on Tuesday. The $49 million raised from the issue will be used to fund pre-clinical research and development activities, contract manufacturing activities, clinical trial activities and for other general corporate purposes, including capital expenditures and working capital, the company said. The offering includes a $2 million investment, or 285,714 shares, purchased directly by Genentech Inc. (NYSE:DNA), Seattle Genetics said. JP Morgan and CIBC World Markets are co-lead managers of the offering, with JP Morgan acting as sole bookrunning manager. Banc of America Securities LLC is acting as a co-manager. The underwriters were also granted the option to purchase an additional 1,007,143 shares of common stock to cover over-allotments, if any, the company said.